Table V.
CYP2C9 (IVS8-109A>T) genotypic and allelic frequencies within samples of healthy volunteers and patients with DMT2 from different regions of the world.
| CYP2C9 (IVS8-109A>T) genotype and allele distribution among healthy volunteers | ||||||||
|---|---|---|---|---|---|---|---|---|
| Reference | Geographic region | Country | N | A/A (n) | A/T (n) | T/T (n) | A (n) | T (n) |
| Hatta et al (25) | Europe | Sweden | 85 | 0.494(42) | 0.376(32)a | 0.129(11)a | 0.682(116)a | 0.318(54)a |
| Maekawa et al (46) | Asia | Japan | 263 | 0.285(75) | 0.517(136)a | 0.198(52)a | 0.544(286)a | 0.456(240)a |
| Lee et al (47) | Korea | 50 | 0.340(17) | 0.480(24)a | 0.180(9)a | 0.580(58)a | 0.420(42)a | |
| Hatta et al (25) | Korea | 128 | 0.406(52) | 0.445(57)a | 0.148(19)a | 0.629(161)a | 0.371(95)a | |
| Dorado et al (26) | Americas | Ecuador | 187 | 0.615(115) | 0.342(64)a | 0.043(8)a | 0.786(294)a | 0.214(80)a |
| Ortega-Vázquez et al (29) | Mexico | 300 | 0.500(150) | 0.430(128)a | 0.070(22)a | 0.710(428)a | 0.290(172)a | |
| DMT2 Mexican-Mestizo patients | ||||||||
| Mexico DMT2 | 248 | 0.714(177) | 0.250(62) | 0.036(9) | 0.839(416) | 0.161(80) | ||
Values are expressed as (%); aP<0.05.